Current Clinical Evidence and Potential Solutions to Increase Benefit of CAR T-Cell Therapy for Patients with Solid Tumors

References

• Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8(9):1069–10. doi:10.1158/2159-8290.CD-18-0367.
   PubMed Web of Science ®Google Scholar
• Geukes Foppen MH, Donia M, Svane IM, Haanen JB. a. G. tumor-infiltrating lymphocytes for the treatment of metastatic cancer. Mol Oncol. 2015;9(10):1918–1935. doi:10.1016/j.molonc.2015.10.018.
   PubMed Web of Science ®Google Scholar
• Vigneron N. Human tumor antigens and cancer immunotherapy. BioMed Res Int. 2015;2015:948501. doi:10.1155/2015/948501.
   PubMed Web of Science ®Google Scholar
• D’Angelo SP, Melchiori L, Merchant MS, Bernstein D, Glod J, Kaplan R, Grupp S, Tap WD, Chagin K, Binder GK, et al. Antitumor activity associated with prolonged persistence of adoptively transferred ny-eso-c259 t cells in synovial sarcoma. Cancer Discov. 2018;8(8):944–957. doi:10.1158/2159-8290.CD-17-1417.
   PubMed Web of Science ®Google Scholar
• Sadelain M, Rivière I, Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer. 2003;3(1):35–45. doi:10.1038/nrc971.
   PubMed Web of Science ®Google Scholar
• Irving BA, Weiss A. The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways. Cell. 1991;64(5):891–901. doi:10.1016/0092-8674(91)90314-O.
   PubMed Web of Science ®Google Scholar
• Kuwana Y, Asakura Y, Utsunomiya N, Nakanishi M, Arata Y, Itoh S, Nagase F, Kurosawa Y. Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions. Biochem. Biophys. Res. Commun. 1987;149(3):960–968. doi:10.1016/0006-291X(87)90502-X.
   PubMed Web of Science ®Google Scholar
• Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc. Natl. Acad. Sci. U. S. A. 1989;86(24):10024–10028. doi:10.1073/pnas.86.24.10024.
   PubMed Web of Science ®Google Scholar
• Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc. Natl. Acad. Sci. U. S. A. 1993;90(2):720–724. doi:10.1073/pnas.90.2.720.
   PubMed Web of Science ®Google Scholar
• Sadelain M, Brentjens R, Rivière I. The promise and potential pitfalls of chimeric antigen receptors. Curr. Opin. Immunol. 2009;21(2):215–223. doi:10.1016/j.coi.2009.02.009.
   PubMed Web of Science ®Google Scholar
• Rossjohn J, Gras S, Miles JJ, Turner SJ, Godfrey DI, McCluskey J. T cell antigen receptor recognition of antigen-presenting molecules. Annu. Rev. Immunol. 2015;33(1):169–200. doi:10.1146/annurev-immunol-032414-112334.
   PubMed Web of Science ®Google Scholar
• Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat Rev Immunol. 2002;2(2):116–126. doi:10.1038/nri727.
   PubMed Web of Science ®Google Scholar
• Hombach A, Wieczarkowiecz A, Marquardt T, Heuser C, Usai L, Pohl C, Seliger B, Abken H. Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule. J Immunol Baltim Md 1950. 2001;167:6123–6131.
   Google Scholar
• Imai C, Mihara K, Andreansky M, Nicholson IC, Pui C-H, Geiger TL, Campana D. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia. 2004;18(4):676–684. doi:10.1038/sj.leu.2403302.
   PubMed Web of Science ®Google Scholar
• Song D-G, Ye Q, Poussin M, Harms GM, Figini M, Powell DJ. CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo. Blood. 2012;119(3):696–706. doi:10.1182/blood-2011-03-344275.
   PubMed Web of Science ®Google Scholar
• Ahmed N, Brawley VS, Hegde M, Robertson C, Ghazi A, Gerken C, Liu E, Dakhova O, Ashoori A, Corder A, et al. Human epidermal growth factor receptor 2 (her2) –specific chimeric antigen receptor–modified t cells for the immunotherapy of her2-positive sarcoma. J. Clin. Oncol. 2015;33(15):1688–1696. doi:10.1200/JCO.2014.58.0225.
   PubMed Web of Science ®Google Scholar
• Ahmed N, Brawley V, Hegde M, Bielamowicz K, Kalra M, Landi D, Robertson C, Gray TL, Diouf O, Wakefield A, et al. HER2-specific chimeric antigen receptor–modified virus-specific t cells for progressive glioblastoma: a phase 1 dose-escalation trial. JAMA Oncol. 2017;3(8):1094. doi:10.1001/jamaoncol.2017.0184.
   PubMed Web of Science ®Google Scholar
• Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, Chew A, Zhao Y, Levine BL, Albelda SM, et al. Mesothelin-specific chimeric antigen receptor mrna-engineered t cells induce antitumor activity in solid malignancies. Cancer Immunol. Res. 2014;2(2):112–120. doi:10.1158/2326-6066.CIR-13-0170.
   PubMed Web of Science ®Google Scholar
• Brown CE, Badie B, Barish ME, Weng  L, Ostberg LR, Chang WC, Naran A, Starr R, Wagner R, Wright C, et al. Bioactivity and safety of il13r 2-redirected chimeric antigen receptor cd8+ t cells in patients with recurrent glioblastoma. Clin. Cancer Res. 2015;21(18):4062–4072. doi:10.1158/1078-0432.CCR-15-0428.
   PubMed Web of Science ®Google Scholar
• Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR, Naranjo A, Ostberg JR, Blanchard MS, Kilpatrick J, Simpson J, et al. Regression of glioblastoma after chimeric antigen receptor T-Cell Therapy. N. Engl. J. Med. 2016;375(26):2561–2569. doi:10.1056/NEJMoa1610497.
   PubMed Web of Science ®Google Scholar
• Feng K, Guo Y, Dai H, Wang Y, Li X, Jia H, Han W. Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer. Sci. China Life Sci. 2016;59(5):468–479. doi:10.1007/s11427-016-5023-8.
   PubMed Web of Science ®Google Scholar
• Feng K, Liu Y, Guo Y, Qiu J, Wu Z, Dai H, Yang Q, Wang Y, Han W. Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers. Protein Cell. 2018;9(10):838–847. doi:10.1007/s13238-017-0440-4.
   PubMed Web of Science ®Google Scholar
• Hege KM, Bergsland EK, Fisher GA, Nemunaitis JJ, Warren RS, McArthur JG, Lin AA, Schlom J, June CH, Sherwin SA, et al. Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer. J Immunother Cancer. 2017;5(1):22. doi:10.1186/s40425-017-0222-9.
   PubMed Web of Science ®Google Scholar
• Junghans RP, Ma Q, Rathore R, Gomes EM, Bais AJ, Lo ASY, Abedi M, Davies RA, Cabral HJ, Al-Homsi AS, et al. Phase I trial of anti-psma designer car-t cells in prostate cancer: possible role for interacting interleukin 2-t cell pharmacodynamics as a determinant of clinical response: car-t cells plus il2 in prostate cancer. Prostate. 2016;76(14):1257–1270. doi:10.1002/pros.23214.
   PubMed Web of Science ®Google Scholar
• Katz SC, Burga RA , McCormack E, Wang LJ, Mooring W, Point GR, Khare PD, Thorn M, Ma Q,  Stainken BF, et al. Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor-modified t-cell therapy for cea+ liver metastases. Clin. Cancer Res. 2015;21(14):3149–3159. doi:10.1158/1078-0432.CCR-14-1421.
   PubMed Web of Science ®Google Scholar
• Lamers CHJ, Klaver Y, Gratama JW, Sleijfer S, Debets R. Treatment of metastatic renal cell carcinoma (mRCC) with CAIX CAR-engineered T-cells–a completed study overview. Biochem. Soc. Trans. 2016;44(3):951–959. doi:10.1042/BST20160037.
   PubMed Web of Science ®Google Scholar
• Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, Rossig C, Russell HV, Diouf O, Liu E, et al. Antitumor activity and long-term fate of chimeric antigen receptor–positive T cells in patients with neuroblastoma. Blood. 2011;118(23):6050–6056. doi:10.1182/blood-2011-05-354449.
   PubMed Web of Science ®Google Scholar
• Louis CU, Straathof K, Bollard CM, Ennamuri S, Gerken C, Lopez TT, Huls MH, Sheehan A, Wu M-F, Liu H, et al. Adoptive transfer of ebv-specific t cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. J Immunother. 2010;33(9):983–990. doi:10.1097/CJI.0b013e3181f3cbf4.
   PubMed Web of Science ®Google Scholar
• O’Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, Martinez-Lage M, Brem S, Maloney E, Shen A, et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med. 2017;9(399):eaaa0984. doi:10.1126/scitranslmed.aaa0984.
   PubMed Web of Science ®Google Scholar
• Tchou J, Zhao Y, Levine BL, Zhang PJ, Davis MM, Melenhorst JJ, Kulikovskaya I, Brennan AL,  Liu X,  Lacey SF, et al. Safety and efficacy of intratumoral injections of chimeric antigen receptor (car) t cells in metastatic breast cancer. Cancer Immunol. Res. 2017;5(12):1152–1161. doi:10.1158/2326-6066.CIR-17-0189.
   PubMed Web of Science ®Google Scholar
• Thistlethwaite FC, Gilham DE, Guest RD, Rothwell DG, Pillai M, Burt DJ, Byatte AJ, Kirillova N, Valle JW, Sharma SK, et al. The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity. Cancer Immunol. Immunother. 2017;66(11):1425–1436. doi:10.1007/s00262-017-2034-7.
   PubMed Web of Science ®Google Scholar
• You F, Jiang L, Zhang B, Lu Q, Zhou Q, Liao X, Wu H, Du K, Zhu Y, Meng H, et al. Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells. Sci. China Life Sci. 2016;59(4):386–397. doi:10.1007/s11427-016-5024-7.
   PubMed Web of Science ®Google Scholar
• Zhang C, Wang Z, Yang Z, Wang M, Li S, Li Y, Zhang R, Xiong Z, Wei Z, Shen J, et al. Phase I escalating-dose trial of car-t therapy targeting cea + metastatic colorectal cancers. Mol Ther. 2017;25(5):1248–1258. doi:10.1016/j.ymthe.2017.03.010.
   PubMed Web of Science ®Google Scholar
• Hanson RL, Hollingsworth MA. Functional consequences of differential o-glycosylation of muc1, muc4, and muc16 (downstream effects on signaling). Biomolecules. 2016;6(3):34. doi:10.3390/biom6030034.
   PubMed Web of Science ®Google Scholar
• Chen J-T, Chen CH,  Ku KL, Hsiao M, Chiang CP, Hsu TL, Chen MH, Wong CH. Glycoprotein B7-H3 overexpression and aberrant glycosylation in oral cancer and immune response. Proc. Natl. Acad. Sci. U. S. A. 2015;112(42):13057–13062. doi:10.1073/pnas.1516991112.
   PubMed Web of Science ®Google Scholar
• Stowell SR, Ju T, Cummings RD. Protein glycosylation in cancer. Annu. Rev. Pathol. 2015;10(1):473–510. doi:10.1146/annurev-pathol-012414-040438.
   PubMedGoogle Scholar
• Saeki N, Gu J, Yoshida T, Wu X. Prostate stem cell antigen: A jekyll and hyde molecule? Clin. Cancer Res. 2010;16(14):3533–3538. doi:10.1158/1078-0432.CCR-09-3169.
   PubMed Web of Science ®Google Scholar
• Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, Huls MH, Liu E, Gee AP, Mei Z, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat. Med. 2008;14(11):1264–1270. doi:10.1038/nm.1882.
   PubMed Web of Science ®Google Scholar
• Gargett T, Yu W , Dotti  G, Yvon ES, Christo SN,  Hayball JD, Lewis ID , Brenner MK,  Brown MP. GD2-specific CAR T cells undergo potent activation and deletion following antigen encounter but can be protected from activation-induced cell death by pd-1 blockade. Mol. Ther. J. Am. Soc. Gene Ther. 2016;24(6):1135–1149. doi:10.1038/mt.2016.63.
   PubMed Web of Science ®Google Scholar
• Scarfò I, Maus MV. Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment. J Immunother Cancer. 2017;5(1):28. doi:10.1186/s40425-017-0230-9.
   PubMed Web of Science ®Google Scholar
• McGranahan N, Swanton C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell. 2017;168(4):613–628. doi:10.1016/j.cell.2017.01.018.
   PubMed Web of Science ®Google Scholar
• Yuan Y. Spatial heterogeneity in the tumor microenvironment. Cold Spring Harb. Perspect. Med. 2016;6(8):a026583. doi:10.1101/cshperspect.a026583.
   PubMed Web of Science ®Google Scholar
• Shah NN, Maatman T, Hari P, Johnson B. Multi targeted car-t cell therapies for b-cell malignancies. Front Oncol. 2019;9:146. doi:10.3389/fonc.2019.00146.
   PubMed Web of Science ®Google Scholar
• Grada Z, Hegde M, Byrd T, Shaffer DR, Ghazi A, Brawley VS, Corder A, Schönfeld K, Koch J, Dotti G, et al. TanCAR: A novel bispecific chimeric antigen receptor for cancer immunotherapy. Mol Ther - Nucleic Acids. 2013;2:e105. doi:10.1038/mtna.2013.32.
   Google Scholar
• Dai H, Wu Z, Jia H, Tong C, Guo Y, Ti D, Han X, Liu Y, Zhang W, Wang C, et al. Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia. J Hematol Oncol J Hematol Oncol. 2020;13(1):30. doi:10.1186/s13045-020-00856-8.
   PubMed Web of Science ®Google Scholar
• Li D, Hu Y, Jin Z, Zhai Y, Tan Y, Sun Y, Zhu S, Zhao C, Chen B, Zhu J, et al. TanCAR T cells targeting CD19 and CD133 efficiently eliminate MLLleukemic cells. Leukemia. 2018;32(9):2012–2016. doi:10.1038/s41375-018-0212-z.
   PubMed Web of Science ®Google Scholar
• Schuberth PC, Hagedorn C, Jensen SM, Gulati P, van den Broek M, Mischo A, Soltermann A, Jüngel A, Marroquin Belaunzaran O, Stahel R, et al. Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells. J. Transl. Med. 2013;11(1):187. doi:10.1186/1479-5876-11-187.
   PubMed Web of Science ®Google Scholar
• Kakarla S, Chow KK, Mata M, Shaffer DR, Song X-T, Wu M-F, Liu H, Wang LL, Rowley DR, Pfizenmaier K, et al. Antitumor effects of chimeric receptor engineered human t cells directed to tumor stroma. Mol. Ther. 2013;21(8):1611–1620. doi:10.1038/mt.2013.110.
   PubMed Web of Science ®Google Scholar
• Tran E, Chinnasamy D, Yu Z, Morgan RA, Lee CCR, Restifo NP, Rosenberg SA. Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia. J. Exp. Med. 2013;210(6):1125–1135. doi:10.1084/jem.20130110.
   PubMed Web of Science ®Google Scholar
• Maude SL, Barrett D, Teachey DT, Grupp SA. Managing cytokine release syndrome associated with novel t cell-engaging therapies. Cancer J. 2014;20(2):119–122. doi:10.1097/PPO.0000000000000035.
   PubMed Web of Science ®Google Scholar
• Giavridis T, van der Stegen SJC, Eyquem J, Hamieh M, Piersigilli A, Sadelain M. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat. Med. 2018;24(6):731–738. doi:10.1038/s41591-018-0041-7.
   PubMed Web of Science ®Google Scholar
• Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, Maus MV, Park JH, Mead E, Pavletic S. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant. 2019;25(4):625–638. doi:10.1016/j.bbmt.2018.12.758.
   PubMed Web of Science ®Google Scholar
• Gust J, Hay KA, Hanafi LA,  Li D,  Myerson D,  Gonzalez-Cuyar LF,  Yeung C,  Liles WC,  Wurfel M,  Lopez JA, et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T Cells. Cancer Discov. 2017;7(12):1404–1419. doi:10.1158/2159-8290.CD-17-0698.
   PubMed Web of Science ®Google Scholar
• Khadka RH, Sakemura R, Kenderian SS, Johnson AJ. Management of cytokine release syndrome: an update on emerging antigen-specific T cell engaging immunotherapies. Immunotherapy. 2019;11(10):851–857. doi:10.2217/imt-2019-0074.
   PubMed Web of Science ®Google Scholar
• Morgan RA, Yang JC,  Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther J Am Soc Gene Ther. 2010;18(4):843–851. doi:10.1038/mt.2010.24.
   PubMed Web of Science ®Google Scholar
• Richman SA, Nunez-Cruz S, Moghimi B, Li LZ, Gershenson ZT, Mourelatos Z, Barrett DM, Grupp SA, Milone MC. High-Affinity GD2-Specific CAR T cells induce fatal encephalitis in a preclinical neuroblastoma model. Cancer Immunol. Res. 2018;6(1):36–46. doi:10.1158/2326-6066.CIR-17-0211.
   PubMed Web of Science ®Google Scholar
• Min IM, Shevlin E, Vedvyas Y, Zaman M, Wyrwas B, Scognamiglio T, Moore MD, Wang W, Park S, Park S, et al. CAR T therapy targeting ICAM-1 eliminates advanced human thyroid tumors. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2017;23(24):7569–7583. doi:10.1158/1078-0432.CCR-17-2008.
   PubMed Web of Science ®Google Scholar
• Park S, Shevlin E, Vedvyas Y, Zaman M, Park S, Hsu YMS, Min IM, Jin MM. Micromolar affinity CAR T cells to ICAM-1 achieves rapid tumor elimination while avoiding systemic toxicity. Sci. Rep. 2017;7(1):14366. doi:10.1038/s41598-017-14749-3.
   PubMed Web of Science ®Google Scholar
• Urbanska K, Lanitis E, Poussin M, Lynn RC, Gavin BP, Kelderman S, Yu J, Scholler N, Powell DJ. A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor. Cancer Res. 2012;72(7):1844–1852. doi:10.1158/0008-5472.CAN-11-3890.
   PubMed Web of Science ®Google Scholar
• Cho JH, Collins JJ, Wong WW. Universal chimeric antigen receptors for multiplexed and logical control of t cell responses. Cell. 2018;173(6):1426–1438.e11. doi:10.1016/j.cell.2018.03.038.
   PubMed Web of Science ®Google Scholar
• Lee YG, Chu H, Lu Y, Leamon CP, Srinivasarao M, Putt KS, Low PS. Regulation of CAR T cell-mediated cytokine release syndrome-like toxicity using low molecular weight adapters. Nat. Commun. 2019;10(1):2681. doi:10.1038/s41467-019-10565-7.
   PubMedGoogle Scholar
• Bachmann M. The UniCAR system: A modular CAR T cell approach to improve the safety of CAR T cells. Immunol Lett. 2019;211:13–22. doi:10.1016/j.imlet.2019.05.003.
   PubMed Web of Science ®Google Scholar
• Piersma B, Hayward M-K, Weaver VM. The fibrotic tumor stroma. Biochim Biophys Acta Rev Cancer. 2020;(2):188356. doi:10.1016/j.bbcan.2020.188356.
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N. Engl. J. Med. 2017;377(26):2531–2544. doi:10.1056/NEJMoa1707447.
   PubMed Web of Science ®Google Scholar
• Rennert P, Dufort F, Su L, Wu L, Birt A, Lobb R, Ambrose C. Hijacking CAR19 T cells to target diverse hematologic and solid tumors. SITC. 2018; abstract #11102.
   Google Scholar
• Moon EK, Carpenito C, Sun J, Wang LCS, Kapoor V, Predina J, Powell DJ, Riley JL, June CH, Albelda SM, et al. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2011;17(14):4719–4730. doi:10.1158/1078-0432.CCR-11-0351.
   PubMed Web of Science ®Google Scholar
• Di Stasi A, De Angelis B, Rooney CM, Zhang L, Mahendravada A, Foster AE, Heslop HE, Brenner MK, Dotti G, Savoldo B, et al. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood. 2009;113(25):6392–6402. doi:10.1182/blood-2009-03-209650.
   PubMed Web of Science ®Google Scholar
• Whilding LM, Halim L, Draper B, Parente-Pereira AC, Zabinski T, Davies DM, Maher J. CAR T-Cells Targeting the Integrin αvβ6 and Co-Expressing the Chemokine Receptor CXCR2 Demonstrate Enhanced Homing and Efficacy against Several Solid Malignancies. Cancers. 2019;11(5):674. doi:10.3390/cancers11050674.
   PubMed Web of Science ®Google Scholar
• Liu G, Rui W, Zheng H, Huang D, Yu F, Zhang Y, Dong J, Zhao X, Zhao X. CXCR2-modified CAR-T cells have enhanced trafficking ability that improves treatment of hepatocellular carcinoma. Eur J Immunol. 2020; doi:10.1002/eji.201948457.
   Web of Science ®Google Scholar
• Jin L, Tao H, Karachi A, Long Y, Hou AY, Na M, Dyson KA, Grippin AJ, Deleyrolle LP, Zhang W, et al. CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors. Nat. Commun. 2019;10(1):4016. doi:10.1038/s41467-019-11869-4.
   PubMed Web of Science ®Google Scholar
• Adusumilli PS, Cherkassky L, Villena-Vargas J, Colovos C, Servais E, Plotkin J, Jones DR, Sadelain M. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci Transl Med. 2014;6(261):261ra151. doi:10.1126/scitranslmed.3010162.
   PubMed Web of Science ®Google Scholar
• Priceman SJ, Tilakawardane D, Jeang B, Aguilar B, Murad JP, Park AK, Chang W-C, Ostberg JR, Neman J, Jandial R, et al. Regional delivery of chimeric antigen receptor–engineered t cells effectively targets her2+breast cancer metastasis to the brain. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2018;24(1):95–105. doi:10.1158/1078-0432.CCR-17-2041.
   PubMed Web of Science ®Google Scholar
• Nellan A, Rota C, Majzner R, Lester-McCully CM, Griesinger AM, Mulcahy Levy JM, Foreman NK, Warren KE, Lee DW. Durable regression of Medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cells. J Immunother Cancer. 2018;6(1):30. doi:10.1186/s40425-018-0340-z.
   PubMed Web of Science ®Google Scholar
• Mulazzani M, Fräßle SP, von Mücke-heim I, Langer S, Zhou X, Ishikawa-Ankerhold H, Leube J, Zhang W, Dötsch S, Svec M, et al. Long-term in vivo microscopy of CAR T cell dynamics during eradication of CNS lymphoma in mice. Proc. Natl. Acad. Sci. U. S. A. 2019;116(48):24275–24284. doi:10.1073/pnas.1903854116.
   PubMed Web of Science ®Google Scholar
• Frigault MJ, Dietrich J, Martinez-Lage M, Leick M, Choi BD, DeFilipp Z, Chen Y-B, Abramson J, Crombie J, Armand P, et al. Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. Blood. 2019;134(11):860–866. doi:10.1182/blood.2019001694.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi:10.1016/j.cell.2011.02.013.
   PubMed Web of Science ®Google Scholar
• Kegler A, Koristka S, Bergmann R, Berndt N, Arndt C, Feldmann A, Hoffmann A, Bornhäuser M, Schmitz M, Bachmann MP, et al. T cells engrafted with a UniCAR 28/z outperform UniCAR BB/z-transduced T cells in the face of regulatory T cell-mediated immunosuppression. Oncoimmunology. 2019;8(9):e1621676. doi:10.1080/2162402X.2019.1621676.
   PubMed Web of Science ®Google Scholar
• Kawalekar OU, O’Connor RS, Fraietta JA, Guo L, McGettigan SE, Posey AD, Patel PR, Guedan S, Scholler J, Keith B, et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T Cells. Immunity. 2016;44(2):380–390. doi:10.1016/j.immuni.2016.01.021.
   PubMed Web of Science ®Google Scholar
• Pegram HJ, Lee JC, Hayman EG, Imperato GH, Tedder TF, Sadelain M, Brentjens RJ. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood. 2012;119(18):4133–4141. doi:10.1182/blood-2011-12-400044.
   PubMed Web of Science ®Google Scholar
• Pegram HJ, Purdon TJ, van Leeuwen DG, Curran KJ, Giralt SA, Barker JN, Brentjens RJ. IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia. Leukemia. 2015;29(2):415–422. doi:10.1038/leu.2014.215.
   PubMed Web of Science ®Google Scholar
• Yeku OO, Purdon TJ, Koneru M, Spriggs D, Brentjens RJ. Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment. Sci. Rep. 2017;7(1):10541. doi:10.1038/s41598-017-10940-8.
   PubMed Web of Science ®Google Scholar
• Koneru M, Purdon TJ, Spriggs D, Koneru S, Brentjens RJ. IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo. Oncoimmunology. 2015;4(3):e994446. doi:10.4161/2162402X.2014.994446.
   PubMed Web of Science ®Google Scholar
• Chinnasamy D, Yu Z, Kerkar SP, Zhang L, Morgan RA, Restifo NP, Rosenberg SA. Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2012;18(6):1672–1683. doi:10.1158/1078-0432.CCR-11-3050.
   PubMed Web of Science ®Google Scholar
• Chmielewski M, Abken H. CAR T Cells Releasing IL-18 Convert to T-Bethigh FoxO1low Effectors that Exhibit Augmented Activity against Advanced Solid Tumors. Cell Rep. 2017;21(11):3205–3219. doi:10.1016/j.celrep.2017.11.063.
   PubMed Web of Science ®Google Scholar
• Foucher ED, Ghigo C, Chouaib S, Galon J, Iovanna J, Olive D. Pancreatic ductal adenocarcinoma: a strong imbalance of good and bad immunological cops in the tumor microenvironment. Front. Immunol. 2018;9:1044. doi:10.3389/fimmu.2018.01044.
   PubMed Web of Science ®Google Scholar
• John LB, Devaud C, Duong CPM, Yong CS, Beavis PA, Haynes NM, Chow MT, Smyth MJ, Kershaw MH, Darcy PK, et al. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2013;19(20):5636–5646. doi:10.1158/1078-0432.CCR-13-0458.
   PubMed Web of Science ®Google Scholar
• Rafiq S, Yeku OO, Jackson HJ, Purdon TJ, van Leeuwen DG, Drakes DJ, Song M, Miele MM, Li Z, Wang P, et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat. Biotechnol. 2018;36(9):847–856. doi:10.1038/nbt.4195.
   PubMed Web of Science ®Google Scholar
• Suarez ER, Chang D-K, Sun J, Sui J, Freeman GJ, Signoretti S, Zhu Q, Marasco WA. Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model. Oncotarget. 2016;7(23):34341–34355. doi:10.18632/oncotarget.9114.
   PubMed Web of Science ®Google Scholar
• Heczey A, Louis CU, Savoldo B, Dakhova O, Durett A, Grilley B, Liu H, Wu MF, Mei Z, Gee A, et al. CAR T cells administered in combination with lymphodepletion and pd-1 inhibition to patients with neuroblastoma. Mol. Ther. J. Am. Soc. Gene Ther. 2017;25(9):2214–2224. doi:10.1016/j.ymthe.2017.05.012.
   PubMed Web of Science ®Google Scholar
• Choi BD, Yu X, Castano AP, Darr H, Henderson DB, Bouffard AA, Larson RC, Scarfò I, Bailey SR, Gerhard GM, et al. CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma. J Immunother Cancer. 2019;7(1):304. doi:10.1186/s40425-019-0806-7.
   PubMed Web of Science ®Google Scholar
• Hu W, Zi Z, Jin Y, Li G, Shao K, Cai Q, Ma X, Wei F. CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions. Cancer Immunol Immunother CII. 2019;68(3):365–377. doi:10.1007/s00262-018-2281-2.
   PubMed Web of Science ®Google Scholar
• Hu B, Zou Y, Zhang L, Tang J, Niedermann G, Firat E, Huang X, Zhu X. Nucleofection with Plasmid DNA for CRISPR/Cas9-mediated inactivation of programmed cell death protein 1 in cd133-specific CAR T Cells. Hum. Gene Ther. 2019;30(4):446–458. doi:10.1089/hum.2017.234.
   PubMed Web of Science ®Google Scholar
• Kloss CC, Lee J, Zhang A, Chen F, Melenhorst JJ, Lacey SF, Maus MV, Fraietta JA, Zhao Y, June CH, et al. Dominant-negative TGF-β receptor enhances psma-targeted human car t cell proliferation and augments prostate cancer eradication. Mol. Ther. 2018;26(7):1855–1866. doi:10.1016/j.ymthe.2018.05.003.
   PubMed Web of Science ®Google Scholar
• Cherkassky L, Morello A, Villena-Vargas J, Feng Y, Dimitrov DS, Jones DR, Sadelain M, Adusumilli PS. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J. Clin. Invest. 2016;126(8):3130–3144. doi:10.1172/JCI83092.
   PubMed Web of Science ®Google Scholar
• Chen N, Morello A, Tano Z, Adusumilli PS. CAR T-cell intrinsic PD-1 checkpoint blockade: A two-in-one approach for solid tumor immunotherapy. Oncoimmunology. 2017;6(2):e1273302. doi:10.1080/2162402X.2016.1273302.
   PubMed Web of Science ®Google Scholar
• Porter CE, Rosewell Shaw A, Jung Y, Yip T, Castro PD, Sandulache VC, Sikora A, Gottschalk S, Ittman MM, Brenner MK, et al. Oncolytic adenovirus armed with bite, cytokine, and checkpoint inhibitor enables car t cells to control the growth of heterogeneous tumors. Mol. Ther. J. Am. Soc. Gene Ther. 2020;28(5):1251–1262. doi:10.1016/j.ymthe.2020.02.016.
   PubMed Web of Science ®Google Scholar
• Morvan MG, Lanier LL. NK cells and cancer: you can teach innate cells new tricks. Nat Rev Cancer. 2016;16(1):7–19. doi:10.1038/nrc.2015.5.
   PubMed Web of Science ®Google Scholar
• Habif G, Crinier A, André P, Vivier E, Narni-Mancinelli E. Targeting natural killer cells in solid tumors. Cell Mol Immunol. 2019;16:415–422. doi:10.1038/s41423-019-0224-2.
   PubMed Web of Science ®Google Scholar
• Muntasell A, Rojo F, Servitja S, Rubio-Perez C, Cabo M, Tamborero D, Costa-Garcia M, Martinez-Garcia M, Menéndez S, Vazquez I, et al. NK cell infiltrates and hla class Iexpression in primary HER2+breast cancer predict and uncouple pathological response and disease-free survival. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2019;25(5):1535–1545. doi:10.1158/1078-0432.CCR-18-2365.
   PubMed Web of Science ®Google Scholar
• Barry KC, Hsu J, Broz ML, Cueto FJ, Binnewies M, Combes AJ, Nelson AE, Loo K, Kumar R, Rosenblum MD, et al. A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments. Nat. Med. 2018;24(8):1178–1191. doi:10.1038/s41591-018-0085-8.
   PubMed Web of Science ®Google Scholar
• Ménard C, Blay J-Y, Borg C, Michiels S, Ghiringhelli F, Robert C, Nonn C, Chaput N, Taieb J, Delahaye NF, et al. Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. Cancer Res. 2009;69(8):3563–3569. doi:10.1158/0008-5472.CAN-08-3807.
   PubMed Web of Science ®Google Scholar
• Melaiu O, Lucarini V, Cifaldi L, Fruci D. Influence of the tumor microenvironment on nk cell function in solid tumors. Front Immunol. 2019;10:3038. doi:10.3389/fimmu.2019.03038.
   PubMed Web of Science ®Google Scholar
• Rezvani K. Adoptive cell therapy using engineered natural killer cells. Bone Marrow Transplant. 2019;54(S2):785–788. doi:10.1038/s41409-019-0601-6.
   PubMedGoogle Scholar
• Li Y, Hermanson DL, Moriarity BS, Kaufman DS. Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity. Cell Stem Cell. 2018;23(2):181–192.e5. doi:10.1016/j.stem.2018.06.002.
   PubMed Web of Science ®Google Scholar
• Han J, Chu J, Keung Chan W, Zhang J, Wang Y, Cohen JB, Victor A, Meisen WH, Kim S-H, Grandi P, et al. CAR-engineered nk cells targeting wild-type egfr and egfrviii enhance killing of glioblastoma and patient-derived glioblastoma stem cells. Sci. Rep. 2015;5(1):11483. doi:10.1038/srep11483.
   PubMed Web of Science ®Google Scholar
• Ao X, Yang Y, Li W, Tan Y, Guo W, Ao L, He X, Wu X , Xia J, Xu X,  et al. Anti-αFR CAR-engineered NK-92 Cells Display Potent Cytotoxicity Against αFR-positive Ovarian Cancer. J Immunother Hagerstown Md 1997. 2019;42:284–296.
   Google Scholar
• Xiao L, Cen D, Gan H, Sun Y, Huang N, Xiong H, Jin Q, Su L, Liu X, Wang K, et al. Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients. Mol. Ther. J. Am. Soc. Gene Ther. 2019;27(6):1114–1125. doi:10.1016/j.ymthe.2019.03.011.
   PubMed Web of Science ®Google Scholar
• Parihar R, Rivas C, Huynh M, Omer B, Lapteva N, Metelitsa LS, Gottschalk SM, Rooney CM. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors. Cancer Immunol. Res. 2019;7(3):363–375. doi:10.1158/2326-6066.CIR-18-0572.
   PubMed Web of Science ®Google Scholar
• Roybal KT, Rupp L, Morsut L, Walker W, McNally K, Park J, Lim W. Precision tumor recognition by t cells with combinatorial antigen-sensing circuits. Cell. 2016;164(4):770–779. doi:10.1016/j.cell.2016.01.011.
   PubMed Web of Science ®Google Scholar
• Srivastava S, Salter AI, Liggitt D, Yechan-Gunja S, Sarvothama M, Cooper K, Smythe KS, Dudakov JA, Pierce RH, Rader C, et al. Logic-gated ror1 chimeric antigen receptor expression rescues t cell-mediated toxicity to normal tissues and enables selective tumor targeting. Cancer Cell. 2019;35(3):489–503.e8. doi:10.1016/j.ccell.2019.02.003.
   PubMed Web of Science ®Google Scholar